secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001725160-25-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027
--------------------------------------------------------------------------------

- Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.
- Azenosertib monotherapy 34.9% ORR (n=43) in Cyclin E1+ PROC from DENALI Part 1b; mDOR 6.3 months.
- FDA Fast Track for azenosertib in PROC. DENALI Part 2 enrollment H1 2025, topline data by end 2026.
- New CEO Julie Eastland, CMO Ingmar Bruns, and other executives appointed in Nov 2024.
- Jan 2025 strategic restructuring to reduce costs; workforce reduction substantially complete Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/0001725160-25-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/zntl-20250326.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer